April 23 (Reuters) - Sanofi SA :
* PRESS RELEASE: RILZABRUTINIB LUNA 3 PHASE 3 STUDY MET PRIMARY ENDPOINT IN IMMUNE THROMBOCYTOPENIA
* REGULATORY SUBMISSIONS IN US AND EU ANTICIPATED BY YEAR-END
Source text for Workspace: Further company coverage:
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587 785 110;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments